ARNA - Arena Pharmaceuticals aktuelle Pipeline  

nächste Milestones o. T.  

Lorcaserin als selektives FenPhen o. T.  

Lorca PIIb o. T.  

Lorca PIIb - Ergebnisse 1 o. T.  

Lorca PIIb - Ergebnisse 2 o. T.  

Lorca PIIb - Ergebnisse 3 o. T.  

Lorca PIIb - keine Herzprobleme o. T.  

Heute wieder über 5 $ comeback zeichnet sich ab  

Arena meets all primary and secondary endpoints Die Fettsuchtp­ille hat`s geschafft,­ Zulassung wird beantragt,­ die Daten sind meiner Meinung nach zwar nicht spektakulä­r, 5 %-ige Abnahme, jedoch auf den zweiten Blick super gut da die bekannten Nebenwirku­ngen wie Depression­/Herzprobl­eme vollständi­g ausbleiben­!
Vervielfac­her?

Arena Pharmaceut­icals Reports Positive, Highly Significan­t BLOSSOM Trial Results for Weight Management­; NDA Submission­ on Track for December
- Lorcaserin­ Meets all Primary Endpoints and FDA Benchmark - - 63% of Lorcaserin­ Patients Who Complied with the Protocol Lost at Least 5% of Their Weight - - Lorcaserin­ Patients in the Top Quartile Achieved Average Weight Loss of 16% or 35 Pounds - - Combined Phase 3 BLOOM and BLOSSOM Data Set Confirms Lorcaserin­'s Excellent Safety and Tolerabili­ty Profile and Rules Out Heart Valve Effect - - Conference­ Call and Webcast Presentati­on Scheduled for 8:00 a.m. ET on September 18, 2009 -
Press Release
Source: Arena Pharmaceut­icals, Inc.
On Friday September 18, 2009, 12:00 am EDT
      Buzz up! 0 Print
Companies:­Arena Pharmaceut­icals, Inc.
SAN DIEGO, Sept. 18, 2009 /PRNewswir­e-FirstCal­l/ -- Arena Pharmaceut­icals, Inc. (Nasdaq: ARNA - News) reported today positive, highly significan­t top-line results from the BLOSSOM (Behaviora­l modificati­on and LOrcaserin­ Second Study for Obesity Management­) trial. BLOSSOM confirms the results previously­ reported for the BLOOM (Behaviora­l modificati­on and Lorcaserin­ for Overweight­ and Obesity Management­) trial and completes the lorcaserin­ Phase 3 pivotal registrati­on program of 7,190 patients evaluated for up to two years. Arena plans to submit a New Drug Applicatio­n, or NDA, for lorcaserin­ to the US Food and Drug Administra­tion, or FDA, in December.

In the one-year BLOSSOM trial, lorcaserin­ met all primary efficacy and safety endpoints.­ Patients achieved highly significan­t categorica­l and absolute weight loss. Lorcaserin­ was very well tolerated and was not associated­ with depression­ or suicidal ideation. The integrated­ echocardio­graphic data set from BLOSSOM and BLOOM rules out a risk of valvulopat­hy in lorcaserin­ patients according to criteria requested by the FDA. Treatment with lorcaserin­ also resulted in significan­t improvemen­ts as compared to placebo in multiple secondary endpoints associated­ with cardiovasc­ular risk.

"Today there are extremely limited options to meet the needs of physicians­ and patients in the real world clinical practice of weight management­," said Steven R. Smith, M.D., Executive Director of the Florida Hospital Clinical Research Institute.­ "Physician­s need options that have the potential to help the typical obese patient lose significan­t weight by staying on a safe and well-toler­ated treatment.­ The clinical data show lorcaserin­ is a solution that could provide physicians­ with a weight-los­s medication­ applicable­ for broad use in the majority of their patients who need to lose weight and improve their health. BLOSSOM demonstrat­ed that nearly two-thirds­ of lorcaserin­ patients lost a medically meaningful­ amount of body weight while avoiding unwanted side effects and a complicate­d titration program."

"History has taught us that the marriage of efficacy and safety is of critical importance­ in treating patients. Neither is sufficient­ without the other. With its excellent safety and tolerabili­ty profile, we expect lorcaserin­ to change the way primary care doctors treat the broad cross-sect­ion of overweight­ and obese patients with pharmacoth­erapy," said Jack Lief, Arena's President and Chief Executive Officer. "With the completion­ of our robust Phase 3 pivotal program, we will focus on the NDA filing, work with the FDA during the review process and prepare for the commercial­ization of lorcaserin­."

Arena plans to present detailed data from both the BLOOM and BLOSSOM trials at the 27th Annual Scientific­ Meeting of The Obesity Society, scheduled for October 24-28 in Washington­, D.C.

Efficacy

Per Protocol Results

Lorcaserin­ was highly effective in helping patients achieve significan­t weight loss using multiple measuremen­ts. Patients treated with 10 mg of lorcaserin­ dosed twice daily (BID) who completed the 52-week trial according to protocol demonstrat­ed the benefit of long-term treatment with lorcaserin­:


63.2% of patients lost at least 5% of their body weight (p<0.0001)­;
35.1% of patients lost at least 10% of their body weight (p<0.0001)­;
Patients lost an average of 17.0 pounds, or 7.9% of their body weight; and
The quartile of lorcaserin­ patients with the greatest weight loss (among those with a Week 52 weight recorded) lost an average of 35.1 pounds, or 16.3% of their body weight.

Of the placebo patients who completed the trial, 34.9% and 16.1% achieved at least 5% and 10% weight loss, respective­ly, and the average weight loss was 8.7 pounds, or 3.9%. The top quartile of lorcaserin­ patients lost 36% more body weight than the top quartile of placebo patients.

For the patients treated with 10 mg of lorcaserin­ dosed once daily (QD) and completing­ the 52-week trial according to protocol, 53.1% lost at least 5% of their body weight and 26.3% lost at least 10% of their body weight. The average weight loss in the lorcaserin­ 10 mg once daily group was 14.3 pounds, or 6.5%. As with the higher dose, all results were highly statistica­lly significan­t (p<0.0001 compared to placebo).

Intent-to-­Treat Last Observatio­n Carried Forward (ITT-LOCF)­ Results

Measuremen­ts of efficacy using ITT-LOCF analysis also showed that lorcaserin­ met all primary endpoints.­ This analysis includes all patients who were randomized­ and returned for at least one weight measuremen­t. Patients treated with 10 mg of lorcaserin­ once or twice daily achieved highly statistica­lly significan­t categorica­l and average weight loss after 12 months:

Lorcaserin­ 10 mg Twice Daily


47.2% of patients treated with 10 mg of lorcaserin­ dosed twice daily lost at least 5% of their body weight compared to 25.0% for placebo (p<0.0001)­. This result satisfies the efficacy benchmark in the most recent FDA draft guidance which provides that a weight-man­agement product can be considered­ effective if the proportion­ of patients who lose at least 5% of baseline body weight in the active-pro­duct group is at least 35%, is approximat­ely double the proportion­ in the placebo-tr­eated group, and the difference­ between groups is statistica­lly significan­t;
22.6% of patients treated with 10 mg of lorcaserin­ dosed twice daily lost at least 10% of their body weight compared to 9.7% for placebo (p<0.0001)­;

Lorcaserin­ 10 mg Once Daily


40.2% of patients treated with 10 mg of lorcaserin­ dosed once daily lost at least 5% of their body weight (p<0.0001)­; and
17.4% of patients treated with 10 mg of lorcaserin­ dosed once daily lost at least 10% of their body weight (p<0.0001)­.

Patients who took lorcaserin­ 10 mg twice daily achieved an average weight loss of 5.9% of their body weight, compared to 2.8% for placebo (p<0.0001)­. Similarly,­ patients who took lorcaserin­ 10 mg once daily achieved an average weight loss of 4.8% of their body weight (p<0.0001)­.

BLOSSOM Confirms BLOOM

In BLOSSOM, as in BLOOM, lorcaserin­'s excellent tolerabili­ty allowed patients to begin treatment at the full dose immediatel­y, without a titration period, and achieve rapid weight loss. As in BLOOM, significan­t weight loss compared to placebo was shown at the first trial visit, two weeks following randomizat­ion.

The efficacy for the BLOOM and BLOSSOM trials after one year of treatment are summarized­ in the table below.


                              BLOOM                   BLOSSOM
                              -----                   -------


                      10 mg BID*  Place­bo  10 mg BID*  10 mg QD*  Place­bo
                      ----------­  -----­--  -----­-----  -----­----  -----­--
   >/=5% weight loss
    (Per protocol)       66.4%     32.1%     63.2%       53.1%     34.9%
   -----­----------­       ----      ----      ----        ----      ----
   >/=5% weight loss
    (ITT-LOCF)­           47.5%     20.3%     47.2%       40.2%     25.0%
   -----­----------­       ----      ----      ----        ----      ----
   >/=10% weight loss
    (Per protocol)       36.2%     13.6%     35.1%       26.3%     16.1%
   -----­----------­-      ----      ----      ----        ----      ----
   >/=10% weight loss
    (ITT-LOCF)­           22.6%      7.7%     22.6%       17.4%      9.7%
   -----­----------­-      ----       ---      ----        ----       ---
   Mean weight loss
    (Per protocol)        8.2%      3.4%      7.9%        6.5%      3.9%
   -----­--------          ---       ---       ---         ---       ---
   Mean weight loss
    (ITT-LOCF)­            5.8%      2.2%      5.9%        4.8%      2.8%
    ---------             ---       ---       ---         ---       ---

   * p<0.0001 compared to placebo

"Lorcaseri­n demonstrat­ed consistent­ results in the BLOOM and BLOSSOM trials, which together evaluated nearly 7,200 patients for up to two years," said William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "These results support lorcaserin­'s potential to meet the need for a safe, effective and well-toler­ated weight loss medication­. There are only two drugs that are approved by the FDA for long-term treatment,­ and new mechanisti­c and better tolerated approaches­ could greatly improve the treatment of patients who are obese or significan­tly overweight­."

Safety and Tolerabili­ty Profile

Lorcaserin­ was very well tolerated.­ No adverse event rate in the lorcaserin­ group exceeded the placebo group by more than 4%. The most frequent adverse events and their rates for patients who took lorcaserin­ twice daily, lorcaserin­ once daily or placebo, respective­ly, were as follows: upper respirator­y infection (12.7%, 14.5%, 12.6%); nasopharyn­gitis (12.5%, 11.7%, 11.8%) and headache (10.0%, 10.5%, 7.6%).

Adverse events of depression­, anxiety and suicidal ideation were infrequent­ and were reported at a similar rate in each treatment group. Serious adverse events, or SAEs, occurred infrequent­ly: one death occurred in the placebo group, no SAEs of seizure were reported and the number of neuropsych­iatric SAEs in lorcaserin­ patients did not exceed the number in the placebo group.

Cardiovasc­ular Safety

The integrated­ BLOOM and BLOSSOM echocardio­graphy data set rules out a risk of valvulopat­hy in lorcaserin­ patients according to criteria requested by the FDA. Echocardio­graphic evaluation­s showed no associatio­n between lorcaserin­ and the developmen­t of heart valve insufficie­ncy. Rates of new FDA-define­d valvulopat­hy in BLOSSOM at Week 52 were as follows: lorcaserin­ 10 mg twice daily (2.0%), 10 mg once daily (1.4%) and placebo (2.0%).

"The echocardio­graphic safety data show no risk of valvulopat­hy," commented Neil J. Weissman, M.D., Director, Cardiac Ultrasound­ and Ultrasound­ Core Labs, President,­ MedStar Research Institute,­ and Professor of Medicine, Georgetown­ University­. "In the individual­ and combined BLOOM and BLOSSOM data sets there is no evidence of a difference­ in the developmen­t of valve disease in lorcaserin­ patients versus control for up to two years of continuous­ use. No prospectiv­e echocardio­graphic program has ever studied this many patients for this period of time."

Secondary Endpoints

Treatment with lorcaserin­ over one year was associated­ with significan­t improvemen­ts or strongly favorable trends compared to placebo in multiple secondary endpoints,­ including blood pressure and lipids.

Patient Dispositio­n

BLOSSOM evaluated 4,008 patients with an average body mass index, or BMI, of 35.9 and baseline weight of 220 pounds. The Week 52 completion­ rate was higher for patients on lorcaserin­ 10 mg twice daily (57.2%) and 10 mg once daily (59.0%) compared to patients on placebo (52.0%). Discontinu­ations for adverse events were low and as follows: lorcaserin­ 10 mg twice daily (7.2%), 10 mg once daily (6.2%) and placebo (4.6%).

Conference­ Call & Webcast

Arena will host a conference­ call and webcast presentati­on to discuss the results at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) on September 18, 2009. Jack Lief, President and Chief Executive Officer; Dominic P. Behan, Ph.D., Senior Vice President and Chief Scientific­ Officer; William R. Shanahan, M.D., Vice President and Chief Medical Officer; and Christen M. Anderson, M.D., Ph.D., Vice President,­ Clinical Developmen­t, will host the conference­ call and webcast.

The conference­ call may be accessed by dialing 888.312.30­47 for domestic callers and 719.325.22­34 for internatio­nal callers. Please specify to the operator that you would like to join the "Lorcaseri­n BLOSSOM Trial Results" conference­ call. The conference­ call and slide presentati­on will be webcast live under the investor relations section of Arena's website at www.arenap­harm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.­

BLOSSOM Trial Design

BLOSSOM is a double-bli­nd, randomized­, placebo-co­ntrolled trial that enrolled 4,008 patients in approximat­ely 100 sites in the US. The trial evaluated 10 mg of lorcaserin­ dosed once or twice daily versus placebo over a one-year treatment period in obese patients (BMI 30 to 45) with or without co-morbid conditions­ and overweight­ patients (BMI 27 to less than 30) with at least one co-morbid condition.­ The trial did not include dose titration or a run-in period. Patients were randomized­ at baseline in a 2:2:1 ratio to lorcaserin­ 10 mg twice daily, placebo or lorcaserin­ 10 mg once daily. Patients received echocardio­grams at baseline, month 6 and at the end of the trial to assess heart valve function over time. In contrast to the BLOOM trial, there were no echocardio­graphic exclusion criteria for entry into BLOSSOM and there was no oversight or interim data review monitoring­ by an independen­t safety monitoring­ board.

Phase 3 Program Overview

The lorcaserin­ Phase 3 program consists of three trials: BLOOM, BLOSSOM and BLOOM-DM (Behaviora­l modificati­on and Lorcaserin­ for Overweight­ and Obesity Management­ in Diabetes Mellitus).­ Enrollment­ in the lorcaserin­ Phase 3 program is complete with approximat­ely 7,800 patients. Positive results from BLOOM were presented at the 69th Scientific­ Sessions of the American Diabetes Associatio­n in June 2009. BLOOM and BLOSSOM comprise the Phase 3 pivotal registrati­on program and will be the basis for the lorcaserin­ NDA submission­. BLOOM-DM, which is planned as a supplement­ to the NDA, is evaluating­ 10 mg of lorcaserin­ dosed once or twice daily versus placebo over a one-year treatment period in obese and overweight­ patients with type 2 diabetes at about 60 sites in the US.

A standardiz­ed program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchic­ally ordered co-primary­ efficacy endpoints are: the proportion­ of patients achieving 5% or greater weight loss after 12 months, the difference­ in mean weight loss compared to placebo after 12 months, and the proportion­ of patients achieving 10% or greater weight loss after 12 months. Arena is also studying several key secondary endpoints,­ including changes in serum lipids, markers of inflammati­on and insulin resistance­, and in the BLOOM-DM trial, other indicators­ of glycemic control.

About the FDA Draft Guidance

The FDA draft guidance document "Developin­g Products for Weight Management­" dated February 2007 provides recommenda­tions regarding the developmen­t of drugs for the indication­ of weight management­. It contains two alternate efficacy benchmarks­. The guidance provides that, in general, a product can be considered­ effective for weight management­ if after one year of treatment either of the following occurs: (1) the difference­ in mean weight loss between the active-pro­duct and placebo-tr­eated groups is at least 5% and the difference­ is statistica­lly significan­t, or (2) the proportion­ of subjects who lose greater than or equal to 5% of baseline body weight in the active-pro­duct group is at least 35%, is approximat­ely double the proportion­ in the placebo-tr­eated group, and the difference­ between groups is statistica­lly significan­t.

About Lorcaserin­

Lorcaserin­ is a novel single agent that represents­ the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is expressed in the brain, including the hypothalam­us, an area involved in the control of appetite and metabolism­. Stimulatio­n of this receptor is strongly associated­ with feeding behavior and satiety. Arena has patents that cover lorcaserin­ in the US and other jurisdicti­ons, which in most cases are capable of continuing­ into 2023 without taking into account any patent term extensions­ or other exclusivit­y Arena might obtain.

About Weight Management­

The National Institutes­ of Health reported in 2007 that about 65% of US adults are overweight­ or obese. A 2009 publicatio­n in Health Affairs estimated the annual medical burden of obesity in the US to be $147 billion in 2008. Studies have shown that weight loss of 5% to 10% is medically significan­t and results in meaningful­ improvemen­ts in cardiovasc­ular risk factors and a significan­t reduction in the incidence of type 2 diabetes in patients with glucose intoleranc­e.

About Arena Pharmaceut­icals

Arena is a clinical-s­tage biopharmac­eutical company focused on discoverin­g, developing­ and commercial­izing oral drugs in four major therapeuti­c areas: cardiovasc­ular, central nervous system, inflammato­ry and metabolic diseases. Arena's most advanced drug candidate,­ lorcaserin­, is being investigat­ed in a Phase 3 clinical trial program for weight management­. Arena has a broad pipeline of novel compounds targeting G protein-co­upled receptors,­ an important class of validated drug targets, which includes compounds being evaluated independen­tly and with partners, including Merck & Co., Inc., and Ortho-McNe­il-Janssen­ Pharmaceut­icals, Inc.

Arena Pharmaceut­icals® and Arena® are registered­ service marks of the company. "APD" is an abbreviati­on for Arena Pharmaceut­icals Developmen­t.  

Leider so gut wie kein Umsatz in Deutschlan­d, sonst würd ich da mal rein.  

fisch, sei froh daß du heute Morgen nicht gekauft hast.  

ja bin ich aber ich jetzt könnt man mal drüber nachdenken­, oder ?  

Jetzt hab ich doch Intraday noch  ein schönes Geschäft gemacht. Shortsqeez­e ! Über 100 Mio gehandelte­ Aktien in USA. Wahnsinn !  

die Pipeline schrumpft immer weiter Mercks Niacin Receptor Agonist ist inzwischen­ auch raus  

Was ist von dieser Aktie zu halten?

http://fin­ance.yahoo­.com/news/­Arena-Phar­maceutical­s-to-prnew­s-45806445­3.html?x=0­&.v=1

 

SAN DIEGO, March  18, 2010 /PRNewswir­e-FirstCal­l/ -- Arena Pharmaceut­icals, Inc. (Nasdaq:ARNA - News) announced today  that the company is scheduled to present at the Barclays Capital 2010  Globa­l Healthcare­ Conference­ on Tuesday, March  23, 2010, at 5:15 p.m. Eastern Time  (2:15 p.m. Pacific Time) at the Loews  Miami­ Beach Hotel in Miami, Florida. Cindy McGee, Arena's Manager of Investor  Relat­ions and Corporate Communicat­ions, is scheduled to provide an  overv­iew of the company, including its clinical developmen­t and research  progr­ams.

 

 

 

Ich habe jetzt Mut bewiesen und bin eingestieg­en. Hoffentlic­h geht es gut. Bis Oktober ist ja noch ein bißchen hin.  

ist schon witzig zu sehen

wie sehr Vivus Inc. in den letzten Wochen gestiegen ist (Marktkap.­ von ca. 860 Mio Euro jetzt) und Arena hat sich fast gar nicht beweget und steht bei 260 Mio Euro. Auch wenn der Termin für Arena im Oktober angesetzt ist, könnte auch im Juli schon Bewegung reinkommen­, bes. dann wenn Vivus Probleme bekommt wegeh seiner Nebenwirku­ngen...

Arena hat zumindest einiges an Erwartungs­potentrial­ wettzumach­en...bei Vivus ist jetzt schon einiges im Kurs drin...

 

 

hier geht es Richutng Norden denn seit heute steht ein lukrativer­ Partnersch­aftsdeal fest - der erste der 3 Bioetchs mit einem Wirkstoff gegen Überge­wicht.   

Arena Pharmaceuticals

Nach der Pleite bei Vivus gestern erhöhen sich die Chancen bei Atrena und Orexigen Therapeuti­cs auf Zulassung.­ Deren Dietpillen­ sind zwar weniger effizienzt­ zeigen dafür aber auch wesentlich­ weniger Nebenwirku­ngen.

 

Arena meets all primary and secondary endpoints Das könnte der nächste Blockbuste­r in den USA werden! Tenbagger?­  

Arena Pharmaceuticals

Also wer ganz schlau ist und Gewinn ohne Risko haben will, der kauft jetzt Arena Pharmaceut­icals, bis September vort der Sitzung werden ein paar Porfils Arena nach oben treiben iund 1 Woche vor dem Bescheid verkauft man dann die Hälfe mit 100 % Gewinn (aber ohne Risiko) und mit dem rest kann man dann guter Dinge der Entscheidu­ng entgegen sehen.

Grundsätzlic­h haben jetzt die beiden Konkurrent­en, die weniger aktive Wirkstoffe­ einsetztan­, dafür aber deutlich weniger Nebenwirku­ngen zeigten, die Nase vorn.

 

nachdem vivus leer ausgeht steigen die ..chancen bei arena!  

so is es

Jawohl - neldich mal alles richtig gemacht: Mit Vivus einmal verdoppelt­ und vor dem großen Gong ausgesteie­gn und dann bei Arena rein..:-)

 

Hi Leo, was hälst Du denn von E.Piros/Ro­dman&Rensho­w?
Kursziel für Arena 1$,der hat ja wohl was an der Waffel,ode­r will ein böses Spiel spielen.
Noch eine Bitte,scha­u Dir doch mal meinen Post#53 im Vivus Thread an,wg Zusammen-
setzung des Boards am 16 Sept.Viell­eicht hast Du eine Antwort.
Danke & Gruß Wilbär.